louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05620797: Immediate Versus Delayed Loading for Implants Retaining Mandibular Complete Overdenture
Official title: Immediate Versus Delayed Loading for Immediately Inserted Implants Retaining Mandibular Complete Overdenture
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Loss
Dental Implant
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2022-11-17
Enrollment: 14
Sex: ALL
Minimum age (years): 55
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study will be to compare the amount of marginal bone height changes between immediate and delayed loading for immediately inserted implants used as abutments of mandibular overdenture.


Eligibility criteria: Inclusion Criteria:

* Patient having two standing mandibular canines with compromised prognosis (which indicted for extraction, without any preapical lesions nor acute infection) and have an adequate labial bone thickness.
* Patient having opposing completely edenteolous maxilla.
* Patients having normal maxilla-mandibular relationship and sufficient inter arch distance was insured by through tentative jaw relation record.
* Patients with good oral hygiene.
* Enough bone volume for implants in the interforaminal region (adequate bone quality and quantity)

Exclusion Criteria:

* Mental disorder patients who are not capable of making a decision or narcotic drug addicts.
* Patients with Tempro-Mandibular Joint disorders
* Patients undergoing radiotherapy or chemotherapy
* Patients with systemic diseases affecting bone metabolism
* Uncooperative patients who have no understanding of the need of a regular follow-up.
* Patient with pathological defects in the areas of implant insertion.
* Vulnerable group as prisoners, mentally retarded patients.

Primary outcomes:
measure: Change in bone loss
timeFrame: at 3 months, 6 months, 9 months, 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams Faculty of Dentistry
Study officials:
References:
Clinical trial NCT03737097: Online Spaced Education to Improve Fall Prevention by Patients With Multiple Sclerosis
Official title: Impact of Online Spaced Education on Long-term Retention of Knowledge About Fall Prevention by Patients With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Education of Patients
Keywords: Fall
Multiple Sclerosis
Lead sponsor: Hospital Israelita Albert Einstein
Sponsor class: OTHER
First posted: 2018-11-09
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Both arms will take place in the same period.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Multiple sclerosis (MS) is a chronic, progressive and neurodegenerative inflammatory disease that affects young adults. In many countries it has been described as the main cause of neurological incapacity in this age group. Due to the neurological impairment, patients with multiple sclerosis have a high incidence of fall. According to studies, MS patients fall three times more than general population. In the present study, the question to be answered is: education of individuals with MS on fall prevention using the method of online spaced education provides better retention of knowledge than the traditional method? This is a clinical trial to compare two methods of education of MS patients for prevention of fall. First stage: Development and validation of materials. Step two: Pilot questions with MS patients. Step three: Intervention and evaluation of outcome.


Eligibility criteria: Inclusion Criteria:

* Multiple sclerosis diagnosis
* Accept to be part in the study
* Have valid e-mail address

Exclusion Criteria:

- Healthcare professionals;

Primary outcomes:
measure: Change in test scores between cohorts measured in weeks 1-24
timeFrame: Months 1-6
Secondary outcomes:
measure: Fall rate
timeFrame: Months 1-6
measure: Adherence to fall prevention strategies
timeFrame: Months 1-6
measure: Individuals satisfaction with the fall prevention education method
timeFrame: Months 3-6
measure: Baseline knowledge levels of patients assessed via their initial responses to the questions
timeFrame: Month 1
measure: Pre and post-test performances differences by age
timeFrame: Month 1-6
measure: Pre and post-test performances differences by gender
timeFrame: Month 1-6
measure: Pre and post-test performances differences by history of falls
timeFrame: Months 1-6
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Sociedade Benef Israelitabras Hospital Albert Einstein
state: Sao Paulo
Study officials:
affiliation: MD
name: Oscar F Santos, PhD
role: STUDY_DIRECTOR
affiliation: Researcher
name: Eliseth R Leão, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00412997: LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Official title: A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tumors
Cutaneous T-Cell Lymphoma
Keywords: advanced solid tumor
Cutaneous T-cell lymphoma
Phase I
HDAC inhibitor
Adult patients
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-12-19
Enrollment: 14
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma


Eligibility criteria: Inclusion Criteria:

* Patients with either a) histologically-confirmed, advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists, or b) cytopathologically confirmed cutaneous T-cell lymphoma (CTCL) whose disease has progressed despite standard therapy or for whom no standard therapy exists. Inclusion is irrespective of stage of disease or extent of prior therapy.
* World Health Organization (WHO) Performance Status of ≤ 2
* Patients must have the adequate laboratory values

Exclusion Criteria:

* Patients with a history of primary CNS tumors
* Patients with any history of brain metastases
* Patients with any peripheral neuropathy ≥ CTCAE grade 2
* Patients with unresolved diarrhea ≥ CTCAE grade 2
* Impairment of cardiac function
* Impairment of gastrointestinal (GI) function or GI disease
* Liver or renal disease

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: To determine the maximum-tolerated dose of LBH589
timeFrame: 1st cycle
Secondary outcomes:
measure: Safety and tolerability assessed by AEs, SAEs and laboratory values.
timeFrame: Every 2 weeks
measure: To characterize the pharmacokinetic (PK) profile of LBH589
timeFrame: every 3 cycles
measure: To assess antitumor activity of LBH589
timeFrame: every 2 cycles
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT05450497: Effect of Sedative Agent on Reducing the Frequency of Arrhythmia in the Patients After Cardiac Surgery
Official title: Effect of Propofol vs Dexmedetomidine or Propofol+Dexmedetomidine on Reducing the Frequency of Arrhythmia in Patients After Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arrythmia
Lead sponsor: Anesthesia Research Group UA
Sponsor class: OTHER
First posted: 2022-07-08
Enrollment: 356
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Arrhythmias early in the recovery period after cardio thoracic surgery are common they develop in 11 to 40 percent of patients after coronary-artery bypass grafting. The right chose of sedative agent could decrease the level of arrhythmia incidence.

Detailed description: Arrhythmias are really common in patients after cardiac surgery. Most of the patients get sedation after cardiac surgery. The goal is to determine if the propofol (PR) (sedative agent), dexmedetomidine (DEX)(selective α2-adrenergic receptor (α2-AR) agonist) or their combination could improve and decrease the incidence of the arrhythmia in patients after cardiac surgery.

Eligibility criteria: Inclusion Criteria:

* Multi vascular lesions of the coronary arteries according to coronary angiography;
* Heart valve damage was confirmed by heart ultrasound, which is subject to surgical correction (aortic stenosis of III degree with a gradient on the aortic valve of more than 42 mmHg, aortic insufficiency III, mitral valve stenosis II-III, mitral regurgitation II-III)
* Age of patients from 18-80 years;

Exclusion Criteria:

* Refusal to participate;
* Hypersensitivity to propofol, dexmedetomidine;
* Acute renal failure that occurred during surgery (ClCr less than 50 ml / h, or a decrease in the rate of diuresis to 0.1 ml / h in the first 4 hours after surgery and does not respond to diuretic therapy)

Primary outcomes:
measure: incidence of arrhythmia
timeFrame: day of the discharge from the hospital (assessed up to day 5)
Secondary outcomes:
Other outcomes:
Locations:
city: Kyiv
country: Ukraine
facility: Medical Network Dobrobut
Study officials:
affiliation: Chief of the anesthesia department
name: Yelyzaveta Plechysta, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05399797: Management of Acute Uncomplicated UTIs in Adults by Community Pharmacists
Official title: Impact of Online Counselling Training For Pharmacists on The Management of Acute Uncomplicated Urinary Tract Infections in Adults; A Double-blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Urinary Tract Infections
Urinary Tract Infection Lower Acute
Keywords: Urinary Tract Infections
Pharmacist
Mystery Patient
Lead sponsor: University of Ibadan
Sponsor class: OTHER
First posted: 2022-06-01
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The pharmacists in the interventional group will receive educational training after baseline assessment while those in the control group will receive the same training at the end of the study
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study is to be conducted in community pharmacies. It involves the use of trained mystery patients to evaluate community pharmacists at baseline and post intervention. The pharmacists will be divided into control and intervention groups using computer generated codes. Those in the intervention group will receive an online training by clinical pharmacists. The training will employ the use of didactic teaching and the use of case studies and simulations covering the diagnosis and management of acute uncomplicated urinary tract infections in adults. Post intervention, mystery patients will revisit the community pharmacists in the control and intervention groups for re-assessment.


Eligibility criteria: Inclusion Criteria:

* The superintendent pharmacist, or the pharmacist manager or any other post National Youth Service Corps pharmacist

Exclusion Criteria:

* Interns, and pharmacists undergoing the mandatory National Youth Service Corps program.

Primary outcomes:
measure: Questioning skill score
timeFrame: Through the study completion (an average of 6 months)
measure: Correct diagnosis of Acute Uncomplicated Urinary Tract Infection
timeFrame: Through the study completion (an average of 6 months)
measure: Appropriate management of urinary tract infection
timeFrame: Through the study completion (an average of 6 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Ibadan
country: Nigeria
facility: University of Ibadan
state: Oyo
Study officials:
affiliation: University of Ibadan
name: Segun J Showande, Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT02279797: Bone Marrow Donation
Official title: Knowledge, Attitudes and Practices About Bone Marrow Donation Among Medical Students and Medical Staff
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bone Marrow Donation
Keywords: bone marrow
attitude
Lead sponsor: International Institute of Rescue Research and Education
Sponsor class: OTHER
First posted: 2014-10-31
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Medical staff: medical doctors, nurses, paramedics Medical students: PhD students, medicine students, nursing and paramedics studies

Brief summary: The study evaluates the knowledge, attitude and practice about bone marrow donation among medical students and medical staff.

Detailed description: In Europe the biggest database of bone marrow donors have Germany - more than 5.5 million people registered, in Poland is only 700 thousand people, and a total worldwide 24 million people willing to donate bone marrow.

In the study the investigators are examining how medical students and medical staff feel about the issues of bone marrow donation, especially: bone marrow shortage, methods of donation.

The investigators are planning to focus on the following specific questions:

What is the level of knowledge about bone marrow donation among participants? What are the sociodemographic, sociocultural and socioeconomic characteristics of listed as an Organ Donor and non-listed as an Organ Donor among participants? Evidence on the role of financial and other incentives in eliciting bone marrow donation.

Eligibility criteria: Inclusion Criteria:

* Give voluntary consent to participate in the study

Exclusion Criteria:

* not meet the above criteria

Primary outcomes:
measure: Percentage of participants who approve prosocial motivation to bone marrow donation
timeFrame: 2 months
Secondary outcomes:
measure: Results of the Medical Knowledge Tool (Questionnaire)
timeFrame: 2 months
measure: Results of the Practice Tool (Questionnaire)
timeFrame: 2 months
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: International Institute of Rescue Research and Education
state: Masovia
city: Warsaw
country: Poland
facility: International Institute of Rescue Research and Education
state: Masovia
Study officials:
affiliation: National Institute of Cardiology, Warsaw, Poland
name: Lukasz Szarpak
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical University of Warsaw
name: Lukasz Czyzewski
role: PRINCIPAL_INVESTIGATOR
affiliation: National Institute of Cardiology, Warsaw, Poland
name: Andrzej Kurowski
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03540797: Myeloid-derived Suppressor Cells in Sepsis
Official title: The Roles of MDSCs (Myeloid-derived Suppressor Cells) in Adult Patients With Sepsis.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sepsis
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2018-05-30
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators will include patients admitted with diagnosis of sepsis in this study.

Sepsis is defined by the consensus committee of American College of Chest Physicians and Society of Critical Care Medicine. The investigators will interview each patient and their family members, and review the medical records to obtain the baseline information including demographic data, clinical diagnosis, and evidence of dementia or psychiatric disorders. Acute physical and chronic health evaluation (APACHE II) score will be rated by chart review of data obtained within 24 hours of admission. The underlying medical history will also be collected.

Brief summary: This study is designed for septic patients, to isolate MDSCs and the correlation of prognosis of sepsis. The purpose of this study hopes to explore the phenomenon and possible mechanisms of MDSCs in patients with severe sepsis.


Eligibility criteria: Inclusion Criteria:

* Patients must have known origin of infection .
* Systemic inflammatory response syndrome.

Exclusion Criteria:

* age less than 18 years
* pregnancy
* known anaphylactoid reaction to colloid fluids
* a life expectancy less than 24 hours,
* inability to provide informed, written consent
* Patients receiving nephrotoxic drugs,
* admitted to the hospital following a surgical procedure,
* sepsis more than 72 hours when screening .

Primary outcomes:
measure: Survival of Intensive care unit (ICU) stay
timeFrame: 28 days
Secondary outcomes:
measure: In hospital survival
timeFrame: 90 days
Other outcomes:
Locations:
city: Linkou
country: Taiwan
facility: Chung Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT03521297: Probiotics in PBC Patients of Poor Response to UDCA
Official title: Safety and Efficacy of Probiotics in Primary Biliary Cholangitis (PBC) Patients With Poor Ursodeoxycholic Acid (UDCA) Response
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Primary Biliary Cholangitis (PBC)
Keywords: Probiotics
ursodeoxycholic acid (UDCA)
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2018-05-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor ursodeoxycholic acid (UDCA) response.

Detailed description: PBC patients with poor ursodeoxycholic acid (UDCA) response are selected and randomly assigned into probiotic group and control group. Patients in probiotic group receive probiotic(Micro V Probiotics) combined UDCA for 6 months and then continue to take UDCA alone. Patients in control group continue to take UDCA alone. Biochemical indicators, immunological indicators, liver stiffness, and ultrasound of the two groups of patients were collected. GLOBE and UK-PBC scoring system are used to assesse prognosis.The feces and serum of all patients are collected to observe the differences in fecal microbial polymorphisms in the two groups of patients. Metabolomics are used to study the differences in the bile acids and short chain fatty acid metabolites of the serum and feces of the two groups of PBC patients.

Eligibility criteria: Inclusion Criteria:

1. PBC patients (diagnosed with PBC according to 2009 AASLD PBC PRACTICE GUIDANCE), take UDCA more than 12 months and have poor response;
2. Age 18-70 years.

Exclusion Criteria:

1. Any other liver disesases (viral hepatitis, HIV positive, alcohol abuse, hemochromatosis, hepatolenticular degeneration, α1-antitrypsin deficiency and so on);
2. Important organ dysfunction such as heart, lung and kidney which affect the life expectancy;
3. Have congenital galactosemia, glucose malabsorption syndrome or lactase deficiency.
4. Patients allergic to research drugs or excipients;
5. Pregnant or lactating women;
6. Not signed informed consent;
7. Have antibiotics one month before enrollment;
8. Microecological preparations (probiotics, prebiotics, synbiotics, etc.) were used before the enrollment;
9. Malignant tumors, nerves and mental disorders;
10. Those who participated in other drug clinical trials in the past 3 months.

Primary outcomes:
measure: Biochemical response
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Third Affliated Hospital of Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Third Affliated Hospital of Sun Yat-sen University
name: Bingliang Lin, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04991597: The Effects of Injection Site Cooling and Solution Buffering on Perceived Pain During Local Anesthesia Administration
Official title: The Effects of Injection Site Cooling and Solution Buffering on Perceived Pain During Local Anesthesia Administration
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Pain
Keywords: Local Anesthesia
Lidocaine
Bicarbonate
Pain
Buffering
Injection Site Cooling
Lead sponsor: Northwell Health
Sponsor class: OTHER
First posted: 2021-08-05
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Palmar aspect of participants forearms will be randomized to have either a cold compress pack or a room temperature compress pack placed on it. The cold compress pack serves as the trial intervention and the room temperature compress pack serves as the placebo. Each forearm will then be injected with both a 3:1 (experimental ratio) and a 9:1 (standard ratio) mixture of lidocaine with epinephrine:sodium bicarbonate in a randomized order.
Primary purpose: OTHER

Brief summary: Participants will have local anesthesia administered to the palmar aspect of both forearms using 4 different injection methods in order to determine which method provides the best results in terms of perceived pain, overall comfort, and participant preference. Injection site cooling and solution buffering using a 3:1 ratio will be compared to the current standard, no injection site cooling and 9:1 solution buffering.


Eligibility criteria: Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures
* Any gender, aged 21 - 65
* In good general health with no peripheral neuropathy or disorders that may produce peripheral neuropathy such as uncontrolled diabetes mellitus
* Healthy intact skin on the palmar aspect of both left and right forearms
* Fluent in English

Exclusion Criteria:

* Current use of any medication
* Pregnancy
* Known allergic reactions to components of the local anesthetic such as sulfites
* History of vasovagal response to venipuncture or vaccination
* History of trauma to the forearms i.e., bone breaks, burns, deep lacerations
* Decreased sensation to the palmar aspect of either forearm

Primary outcomes:
measure: Pain from Needle Insertion
timeFrame: 2 Months
measure: Pain from Solution Deposition
timeFrame: 2 Months
measure: Overall Comfort Level During Injection
timeFrame: 2 Months
Secondary outcomes:
measure: Injection Method Preference
timeFrame: 2 Months
Other outcomes:
measure: Buffered Anesthetic Solution pH
timeFrame: 2 Months
Locations:
Study officials:
affiliation: Northwell Health
name: Nicholas Bastidas, MD
role: PRINCIPAL_INVESTIGATOR
References: